Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Consistency of MGMT Promoter Methylation Levels in Recurrent Gliomas and Its Impact on Temozolomide Rechallenge

  • By

  • Henry Noren

  • Gabriella Pelofsky

  • Brianna Suffren

  • Laura Mittelman

  • Christine Yohn

  • Aminah Twyman

  • Christopher A. Febres-Aldana

  • Arevik Abramyan

  • Aparna Sertil

  • Randy S. D’Amico

  • Jonathan H. Sherman

  • Morana Vojnic

  • September 16, 2026

Share

  • 1

    MGMT promoter methylation is a predictor of sensitivity to alkylating chemotherapy and correlates with survival in glioma patients.

  • 2

    Studies show 70-85% stability of MGMT methylation levels between primary and recurrent gliomas, but some tumors may acquire or lose methylation.

  • 3

    MGMT methylation is increasingly viewed as a quantitative continuum, challenging the reliability of binary classification in treatment decisions.

  • 4

    Patients with retained MGMT hypermethylation benefit more from temozolomide rechallenge compared to those with unmethylated tumors.

  • 5

    The study aims to clarify the clinical relevance of reassessing MGMT methylation at recurrence to inform precision treatment strategies.

Original Source(s)

Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge

  • by Henry Noren, Gabriella Pelofsky, Brianna Suffren, Laura Mittelman, Christine Yohn, Aminah Twyman, Christopher A. Febres-Aldana, Arevik Abramyan, Aparna Sertil, Randy S. D’Amico, Jonathan H. Sherman, Morana Vojnic

  • September 16, 2026

Related Content

CAR T Before Surgery Improves Glioblastoma Control in Mice

Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

  • September 7, 2026

  • 3 min
Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min
Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma